Adalank
N-Acetyl Selank Amidate / Enhanced Selank / Selank analog
A modified version of Selank — N-acetylated and amidated at both ends of the peptide chain. These modifications are believed to increase resistance to enzymatic degradation and potentially extend duration of action compared to standard Selank. Carries the same anxiolytic and cognitive enhancement research interest as Selank but with significantly less published research behind the specific modification.
Mechanism of action
Same base mechanism as Selank — modulation of GABA-A receptor expression without direct binding, BDNF elevation, cytokine modulation. The N-acetyl amidate modification is intended to slow enzymatic breakdown, potentially producing longer-lasting effects at lower doses compared to standard Selank. This modification logic is pharmacologically sound but has not been validated in published comparative human research.
Effects in the body
Adalank is essentially a next-generation Selank formulation. If Selank already exists in your research interest (see the Selank profile), Adalank represents a modified delivery of the same core mechanism rather than a fundamentally new compound. The modification may produce different duration or potency characteristics — but this is theoretical based on the chemistry rather than demonstrated in controlled research.
Pros & cons (from the literature)
- Same mechanistic base as Selank — anxiolytic without sedation, BDNF elevation, immune modulation
- N-acetyl amidate modification may extend duration of action
- Intranasal administration available — no injection required
- Lower dose requirement theoretically based on enhanced stability
- Evidence tier 1 — almost no published research on the specific Adalank modification versus standard Selank
- All claimed advantages over Selank are theoretical based on chemistry not demonstrated in controlled studies
- No human clinical data
- Standard Selank has significantly more published research if the same mechanism is the research interest
Protocol summary (from published research)
Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.
FDA & regulatory status
Evidence base
No published peer-reviewed research on Adalank specifically. Evidence inherited conceptually from Selank parent compound. Pharmacological rationale for modification is sound but unvalidated.
Primary research sources
Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.